newsfilter
← Latest News
Business Wire·

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first multiple-ascending-dose